Interstitial Lung Disease Burden Is Rising Faster Than the World Can Measure
Global estimates of interstitial lung disease remain frustratingly imprecise, yet the direction of travel is hard to miss. Across multiple populations, incidence and prevalence have increased over time, even as the field continues to struggle with inconsistent case definitions, uneven diagnostic access, and the absence of comparable reporting systems across countries.
The problem is not only scientific; it is structural. ILD is a heterogeneous group of disorders, and the burden of disease shifts with local exposures, smoking patterns, occupational hazards, access to specialist imaging, and the ability of health systems to recognize fibrotic lung disease before respiratory failure sets in. In that setting, a crude global average can obscure very different realities on the ground.
Idiopathic pulmonary fibrosis remains the most studied and most visible subtype, but it is only one part of a much broader and more uneven burden. Connective tissue disease-associated ILD and hypersensitivity pneumonitis vary substantially by geography, reflecting differences in autoimmune disease prevalence, environmental antigens, farming and bird exposures, and diagnostic customs. In many regions, cases are still identified late, after irreversible fibrosis has already advanced.
The burden is not evenly distributed, and neither is the ability to count it.
The Best-Studied ILDs Still Leave Most of the Field in the Dark
The review centers on the limited evidence base available for idiopathic pulmonary fibrosis, connective tissue disease-associated ILD, hypersensitivity pneumonitis, and sarcoidosis. Those diagnoses account for most of the available epidemiologic data, but they do not exhaust the global disease spectrum. Outside those categories, data remain sparse for many other ILDs, leaving clinicians and policymakers without reliable estimates of how frequently these disorders occur, how often they are missed, or how much disability they produce.
That gap has clinical consequences. Without accurate incidence and prevalence data, health systems cannot plan for specialist referrals, pulmonary rehabilitation, antifibrotic access, transplant pathways, or long-term oxygen needs. In countries where pulmonary fibrosis is recognized late or underdiagnosed entirely, mortality may be attributed to nonspecific respiratory failure rather than a named interstitial process, further flattening the epidemiologic picture.
Geographic variability is especially pronounced for connective tissue disease-associated ILD and hypersensitivity pneumonitis. Both disorders depend heavily on local prevalence of causative autoimmune diseases or inhaled antigens, and both can be missed when clinicians lack access to high-resolution computed tomography, multidisciplinary review, or exposure history assessment. In practical terms, the same disease may look rare in one region and common in another simply because one health system is capable of finding it.
Uneven Access Distorts the Epidemiology as Much as the Biology
Access to health care remains uneven, particularly in low-income and middle-income countries, where specialist evaluation, imaging, pathology, and longitudinal follow-up may be limited. That imbalance creates a double burden: patients face delayed diagnosis and limited treatment, while researchers are left with incomplete datasets that undercount disease incidence and prevalence.
Socioeconomic inequality also shapes outcomes within countries, not just between them. Patients with lower income, weaker insurance coverage, or residence far from tertiary centers often face later presentation and less consistent follow-up. In ILD, delay is expensive biologically. Fibrosis does not wait for administrative systems to catch up, and every missed month can mean more lost lung function, more dyspnea, and fewer therapeutic options.
The review also points to exposure-related and environmental factors as major contributors to disease burden. Occupational and household exposures, air pollution, and other environmental risks are increasingly relevant as investigators try to explain why the incidence of fibrotic lung disease appears to be climbing. These factors do not act in isolation. Genetic susceptibility, immune dysregulation, and cumulative inhalational injury likely intersect over years before disease becomes clinically apparent.
New Data Tools Could Change What Gets Counted
A major shift is underway in ILD epidemiology research. Nationwide health-care databases now allow investigators to identify cases across large populations, track outcomes over time, and compare trends between regions with greater precision than older clinic-based studies ever allowed. Monitoring of air pollution exposure adds another layer, opening the door to more realistic assessments of environmental contribution.
These tools are useful because ILD is rarely a single-event diagnosis. It emerges from patterns: progressive cough, exertional dyspnea, abnormal imaging, physiologic decline, and, in some patients, sudden acceleration toward respiratory failure. Population datasets can capture those trajectories at scale, but only if case ascertainment is accurate and coding systems are robust enough to distinguish one ILD subtype from another.
Even then, important questions remain unresolved. The review makes clear that the field is still at an early stage in understanding how genetic risk and environmental exposure combine to drive the rising burden of these diseases. The biology is plausible: repeated epithelial injury, maladaptive repair, and chronic immune activation can converge on fibrosis, but the epidemiology has not yet caught up with the mechanistic story.
Mortality, Disability, and Health-System Strain Extend Beyond Prevalence Numbers
The burden of ILD cannot be reduced to case counts alone. These are often disabling and frequently fatal diseases, with consequences that extend to caregiver burden, work loss, reduced quality of life, and escalating use of specialist care. Even in well-resourced settings, the disease course can be difficult to predict, and in under-resourced settings the path from symptom onset to diagnosis may be so long that clinicians first encounter patients in advanced disease.
Sarcoidosis remains among the better described nonfibrotic ILDs, yet for many other conditions epidemiologic visibility is minimal. That imbalance shapes research funding, clinical guideline development, and public health planning. The diseases with the loudest datasets attract the most attention, while rarer or less consistently coded ILDs remain buried inside broad respiratory categories.
The result is a field in which the actual burden is almost certainly larger than the published burden. The central challenge is not just estimating how many people have ILD, but identifying who is being missed, where they live, what exposures they face, and why diagnostic pathways fail.
Why the Next Phase of ILD Epidemiology Will Depend on Better Case Capture
Future progress depends on harmonizing case definitions, improving registry quality, and linking clinical data with environmental and socioeconomic information. Without those steps, global comparisons will remain fragile and heavily influenced by local diagnostic practice rather than true disease frequency.
Better data will matter most in places where health systems are least able to absorb an expanding ILD burden. If the current rise in incidence and prevalence continues, the number of patients requiring specialist lung care, antifibrotic therapy, and long-term monitoring will increase as well. In countries already dealing with constrained access to respiratory care, that pressure will be felt quickly.
The review leaves one clear message: ILD is no longer an epidemiologic curiosity confined to specialty centers. Its global burden is growing, but the world still lacks a complete map of where these diseases occur, who is affected, and which exposures are driving them. Until those questions are answered with better data, the field will continue to underestimate a set of lung diseases that are often diagnosed late and difficult to reverse.